Skip to content

Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis

Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels During Emergency Management of Rhabdomyolysis: Predicting Renal Failure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01544231
Enrollment
197
Registered
2012-03-05
Start date
2013-08-31
Completion date
2015-12-09
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Failure, Rhabdomyolysis

Keywords

Neutrophil Gelatinase Associated Lipocalin, predicting acute kidney failure, emergency room

Brief summary

This research project consists of a prospective diagnostic study conducted on patients with clinical suspicion of rhabdomyolysis admitted to the emergency rooms of the University Hospitals of Nimes, Montpellier, Paris, Nice and Toulon Inter Army Hospital. The main objective of this study is to determine whether the plasma level of Neutrophil Gelatinase Associated Lipocalin (NGAL) may be retained as a predictor of acute renal failure (ARF) occurring within 48 hours after admission for rhabdomyolysis.

Detailed description

The secondary objectives of this are: * to study plasma NGAL levels on admission to the emergency ward as a marker of morbidity and mortality by considering the following factors: duration of hospitalization, need for extracorporeal blood purification, ICU admission, death. * to study the delay between the onset of the proposed cause of rhabdomyolysis and treatment initiation * to study the delay between treatment initiation and the occurrence of ARF.

Interventions

BIOLOGICALPlasma NGAL level

The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * Patient hospitalized with Creatine Phospho-Kinase \> 1000 UI/l

Exclusion criteria

* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * Chronic renal insufficiency with dialysis * The patient has an acute coronary syndrome * Nephrotoxic medications within 72 hours prior to admission * Need for a procedure involving the injection of iodine * Patient in shock * Occurrence of acute renal failure can be explained by a cause other than rhabdomyolysis.

Design outcomes

Primary

MeasureTime frameDescription
Plasma NGAL levelAdmittance to the ermergency room (ie at baseline)ng/ml

Secondary

MeasureTime frameDescription
Delay between cause and treatmentDay 2Hours elapsed between proposed cause of rhabdomyolysis and treatment initiation measured in hours.
Need for extracorporeal blood purificationHospital discharge (expected average of 2-3 days)yes/no
Delay between initiation of treatment and beginning of acute renal failureDay 2meaured in hours
Length of hospitalizationHospital discharge (expected average of 2-3 days)measured in days
Patient deceased during hospitalizationHospital discharge (expected average of 2-3 days)yes/no
Patient admitted to ICU?Hospital discharge (expected average of 2-3 days)yes/no

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026